BusinessMelinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in EuropeBy Nasdaq OMXMar 8, 2018, 12:01 PM UTC
BusinessMelinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in ArgentinaBy Nasdaq OMXFeb 20, 2018, 12:01 PM UTC
BusinessMelinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United StatesBy Nasdaq OMXJan 29, 2018, 12:00 PM UTC
BusinessMelinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United StatesBy Nasdaq OMXOct 30, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeekBy Nasdaq OMXOct 4, 2017, 5:14 PM UTC
BusinessMelinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)By Nasdaq OMXJun 19, 2017, 8:30 PM UTC
BusinessCempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial ResultsBy Nasdaq OMXFeb 28, 2017, 11:45 AM UTC
BusinessCempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSIBy Nasdaq OMXFeb 24, 2017, 12:00 PM UTC
